CPRX
CATALYST PHARMACEUTICALS, INC.Company Information
- Company Name
- CATALYST PHARMACEUTICALS, INC.
- CIK
- CIK0001369568
- Category
- Large accelerated filer
- Ticker: Exchange
- CPRX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CPRX
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2025-12-12
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 862,541
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 103,565,505
- Shares outstanding
- 122,254,171
- Ownership
- 84.71%
Earnings Market Reaction
- Filing date
- 2026-05-11
- Price on filing date
- —
- 1-month reaction
- 0.39%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 756 | 709 | 690 | 653 | 581 | 518 | 442 | 376 | 310 | 138 | 121 | 179 | ||||||
| Accounts Receivable Net Current | 131 | 126 | 106 | 66 | 71 | 65 | 58 | 57 | 60 | 54 | 48 | 43 | ||||||
| Inventory Net | 35 | 37 | 28 | 19 | 20 | 20 | 20 | 18 | 20 | 16 | 9 | 11 | ||||||
| Prepaid Expense And Other Assets Current | 19 | 21 | 28 | 21 | 14 | 21 | 18 | 24 | 14 | 13 | 14 | 9 | ||||||
| Assets Current | 940 | 894 | 852 | 759 | 686 | 624 | 539 | 474 | 405 | 219 | 192 | 241 | ||||||
| Operating Lease Right Of Use Asset | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Finite Lived Intangible Assets Net | 122 | 132 | 129 | 138 | 147 | 157 | 166 | 175 | 185 | 194 | 167 | 176 | ||||||
| Deferred Income Tax Assets Net | 55 | 53 | 48 | 51 | 48 | 46 | 48 | 40 | 38 | 37 | 37 | 23 | ||||||
| Equity Securities F V N I Noncurrent | 27 | 23 | 19 | 21 | 24 | 22 | 15 | 13 | 15 | 16 | 13 | - | ||||||
| Assets | 1,148 | 1,104 | 1,052 | 972 | 909 | 851 | 772 | 706 | 647 | 470 | 413 | 444 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 7 | 11 | 9 | 6 | 11 | 17 | 12 | 7 | 10 | 15 | 5 | 4 | ||||||
| Accrued Liabilities Current | 125 | 136 | 120 | 107 | 100 | 104 | 94 | 85 | 69 | 61 | 53 | 48 | ||||||
| Liabilities Current | 132 | 147 | 129 | 113 | 112 | 121 | 105 | 92 | 80 | 76 | 58 | 53 | ||||||
| Operating Lease Liability Noncurrent | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 3 | 3 | 4 | 13 | ||||||
| Liabilities | 135 | 150 | 131 | 116 | 115 | 124 | 111 | 98 | 85 | 82 | 65 | 69 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 489 | 480 | 473 | 462 | 452 | 442 | 432 | 423 | 417 | 266 | 262 | 258 | ||||||
| Retained Earnings Accumulated Deficit | 523 | 474 | 447 | 394 | 342 | 285 | 229 | 185 | 145 | 121 | 86 | 117 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Stockholders Equity | 1,013 | 954 | 920 | 856 | 794 | 728 | 661 | 609 | 561 | 388 | 349 | 375 | ||||||
| Liabilities And Stockholders Equity | 1,148 | 1,104 | 1,052 | 972 | 909 | 851 | 772 | 706 | 647 | 470 | 413 | 444 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 122 | 123 | 123 | 122 | 122 | 121 | 119 | 119 | 118 | 107 | 107 | 107 | ||||||
| Shares Outstanding | 122 | 123 | 123 | 122 | 122 | 121 | 119 | 119 | 118 | 107 | 107 | 107 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCATALYST PHARMACEUTICALS, INC. (CPRX) — SEC Financial Statements & Analysis
CATALYST PHARMACEUTICALS, INC. (CPRX) is a pharmaceutical preparations company, incorporated in DE. CATALYST PHARMACEUTICALS, INC. trades on Nasdaq as: CPRX. CATALYST PHARMACEUTICALS, INC. (CPRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-11. Based on that filing, On profitability, CATALYST PHARMACEUTICALS, INC. posts a gross margin of 85.96%, an operating margin of 44.83%, a net margin of 37.08%, a Return on Equity (ROE) of 24.50%, a Return on Assets (ROA) of 21.52%, and a Return on Invested Capital (ROIC) of 81.04%. Per share, it reports EPS of $1.81, diluted EPS of $1.74, free cash flow per share of $1.70, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 11.65% year-over-year, net income growth of 12.15% year-over-year, and EPS growth of 11.43% year-over-year. On the balance sheet, it maintains a current ratio of 7.10x, a quick ratio of 6.70x, working capital of $807.99M, a debt-to-equity ratio of 0.13x, a debt ratio of 0.12, free cash flow of $208.13M (TTM), and net debt of $-755.86M. Figures sourced from SEC EDGAR.
- EPS TTM
- $1.81
- ROE TTM
- 24.50%
- ROA TTM
- 21.52%
- Debt To Equity
- 0.13x
- Free Cash Flow TTM
- $208.13M
- Net Revenue TTM Growth 1Y
- 11.65%
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is CATALYST PHARMACEUTICALS, INC. in?
CATALYST PHARMACEUTICALS, INC. (CPRX) operates in the Pharmaceutical Preparations industry.
What exchange does CPRX trade on?
CATALYST PHARMACEUTICALS, INC. (CPRX) trades on the Nasdaq.
Where is CATALYST PHARMACEUTICALS, INC. incorporated?
CATALYST PHARMACEUTICALS, INC. is incorporated in DE.
When was CATALYST PHARMACEUTICALS, INC. (CPRX)'s most recent SEC filing?
CATALYST PHARMACEUTICALS, INC. (CPRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-11.
What is CPRX's EPS (earnings per share)?
CATALYST PHARMACEUTICALS, INC. (CPRX)'s trailing twelve month EPS is $1.81 as of 2026-03-31.
What is CPRX's ROE (return on equity)?
CATALYST PHARMACEUTICALS, INC. (CPRX)'s trailing twelve month Return on Equity (ROE) is 24.50% as of 2026-03-31.
What is CPRX's ROA (return on assets)?
CATALYST PHARMACEUTICALS, INC. (CPRX)'s trailing twelve month Return on Assets (ROA) is 21.52% as of 2026-03-31.
What is CPRX's ROIC (return on invested capital)?
CATALYST PHARMACEUTICALS, INC. (CPRX)'s trailing twelve month Return on Invested Capital (ROIC) is 81.04% as of 2026-03-31.